Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease
Latest Information Update: 06 Nov 2021
At a glance
- Drugs RG 125 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 05 Feb 2020 Status changed from active, no longer recruiting to completed.
- 30 Aug 2018 Planned End Date changed from 30 Nov 2018 to 28 Dec 2020.
- 30 Aug 2018 Planned primary completion date changed from 30 Nov 2018 to 28 Dec 2020.